MRUS Jan 2025 50.000 put
| Previous close | 6.10 |
| Open | 5.80 |
| Bid | 6.30 |
| Ask | 8.50 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 5.80 - 5.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 353 |
Globe NewswireMerus Announces Pricing of Upsized Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purch
Simply Wall St.These Analysts Think Merus N.V.'s (NASDAQ:MRUS) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Merus N.V. ( NASDAQ:MRUS ), with the analysts making...
- Globe Newswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 a.m. ET. The webcast of the presentation will be contemporaneous
